NCT00581854View on ClinicalTrials.gov

Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 30, 2000

Primary Completion Date

June 30, 2006

Study Completion Date

March 31, 2010

Conditions
Mantle Cell Lymphoma
Interventions
DRUG

modified Hyper-CVAD

rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years

Trial Locations (1)

53792

UWCCC, Madison

All Listed Sponsors
lead

University of Wisconsin, Madison

OTHER

NCT00581854 - Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter